Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Xenetic Biosciences (NASDAQ: XBIO) has signed a definitive all-stock share exchange agreement to acquire Santersus AG, with the combined company to be renamed Santersus Bio, Inc. and trade on Nasdaq under a new ticker, SNTS. On a pro forma fully diluted basis, current Xenetic equity holders will own approximately 15.0% of the combined company while Santersus holders receive about 85.0%, subject to adjustment based on Xenetic's net cash at closing. The deal is expected to close in Q4 2026, pending Xenetic stockholder approval, Nasdaq listing of the new shares, and effectiveness of a resale S-1.
Key figures
- Board size
- 8
- New ticker
- SNTS
- Lockup days
- 180
- Deal structure
- all-stock share exchange; no cash consideration or deal value disclosed
- Expected close
- Q4 2026
- Combined company name
- Santersus Bio, Inc.
- Board nominees xenetic
- 2
- Board nominees santersus
- 6
- Pro forma ownership xbio holders
- 15.0%
- Fda breakthrough device designations
- 2
- Pro forma ownership santersus holders
- 85.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.